Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
Download pdf
Abstract/Description: | A method of delivering a medicament to the surface of a cancer cell and transferring the medicament into the cancer cell using an activated plasminogen activator material such as a plasminogen activator inhibitor type-1 or type-2 (PAI-1, PAI-2). The medicament is coupled to PAI-1 or PAI-2 to form a reaction product that is coupled with the urokinase plasminogen activator (uPA) that is bound to the cell surface by the uPA receptor (uPAR). The medicament is coupled to PAI-1 or PAI-2 (for example, using a preserving agent such as saporin) in such a way that the medicament does not interfere with active sites responsible for binding to uPA or LRP proteins responsible for the internalization of the plasminogen activator material/conjugated medicament. The conjugated medicament prevents the conversion of the plasminogen activator inhibitor material into its latent inactive form. The resulting complex is internalized into the cancer cell to deliver the medicament within the cell. |
---|---|
Subject(s): | 424/193.1 424/197.11 424/542 435/326 435/346 977/806 977/906 977/911 977/912 977/915 977/920 |
Date Issued: | 1997-10-21 |
Title: | Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material. |
|
---|---|---|
Name(s): |
The University of Toledo, assignee Jankun, Jerzy, inventor Hart, Richard, inventor |
|
Type of Resource: | text | |
Genre: | patent | |
Publisher: | United States Patent and Trademark Office | |
Other Date: | Date Filed: 1996-05-08 | |
Date Issued: | 1997-10-21 | |
Physical Form: | application/pdf | |
Extent: | 10 p. | |
Abstract/Description: | A method of delivering a medicament to the surface of a cancer cell and transferring the medicament into the cancer cell using an activated plasminogen activator material such as a plasminogen activator inhibitor type-1 or type-2 (PAI-1, PAI-2). The medicament is coupled to PAI-1 or PAI-2 to form a reaction product that is coupled with the urokinase plasminogen activator (uPA) that is bound to the cell surface by the uPA receptor (uPAR). The medicament is coupled to PAI-1 or PAI-2 (for example, using a preserving agent such as saporin) in such a way that the medicament does not interfere with active sites responsible for binding to uPA or LRP proteins responsible for the internalization of the plasminogen activator material/conjugated medicament. The conjugated medicament prevents the conversion of the plasminogen activator inhibitor material into its latent inactive form. The resulting complex is internalized into the cancer cell to deliver the medicament within the cell. | |
Identifier(s): |
utpatents-US5679350 (IID) Patent No.: US5679350 (patno) Appl. No.: 08/646561 (appno) |
|
Subject(s): |
424/193.1 424/197.11 424/542 435/326 435/346 977/806 977/906 977/911 977/912 977/915 977/920 |
|
Held by: | United States Patent and Trademark Office (USPTO) Public Search Facility | |
Location: | University of Toledo Digital Repository | |
Rights Statement: | No Copyright - United States | |
In Collections: |